PEDIATRICS Vol. 58 No. 6 December 1976, pp. 787-790
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bryan, H.
Right arrow Articles by Angel, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bryan, H.
Right arrow Articles by Angel, A.

Intralipid–Its rational use in parenteral nutrition of the newborn

Heather Bryan M.D.1, Andrew Shennan M.B.1, Elizabeth Griffin M.B.1, and Aubie Angel M.D.1

1 Research Institute of the Hospital for Sick Children, Division of Endocrinology and Metabolism, Toronto General Hospital, and the Departments of Pediatrics and Medicine, University of Toronto, Toronto, Ontario, Canada

The recent release of Intralipid by the FDA has made available a calorie-dense and nutritious supplement to parenteral feeding regimens. Since it was first developed and introduced in 1961 by Wretlind and co-workers in Sweden, a large and successful experience has accrued in Europe and Canada in patients with burns, severe malnutrition, gastrointestinal disorders, and anomalies. It has not, however, been widely used in newborn infants. In general, complications are rare and anaphylactic reactions experienced with the use of earlier intravenous fat emulsions are not seen.1 Intralipid is a 10% emulsion of soybean oil stabilized with 1.2% egg phospholipid with a particle size less than 1 mµ and metabolic fate similar to naturally occurring chylomicrons.